• OPEN AN ACCOUNT
Indian Indices
Sensex
73,123.83 -125.56
( -0.17%)
Global Indices
Nasdaq
52,891.50 14.41
(0.03%)
Dow Jones
7,684.38 -93.79
(-1.21%)
Hang Seng
62,584.98 -322.86
(-0.51%)
Nikkei 225
10,723.99 -28.89
(-0.27%)
Forex
USD-INR
94.51 -0.31
(-0.33%)
EUR-INR
106.10 -0.35
(-0.33%)
GBP-INR
126.51 -0.13
(-0.10%)
JPY-INR
0.60 0.00
(-0.28%)

EQUITY - MARKET SCREENER

SBI Life Insurance Company Ltd
Industry :  Finance & Investments
BSE Code
ISIN Demat
Book Value()
540719
INE123W01016
200.5278462
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
SBILIFE
63.97
166365.25
EPS(TTM)
Face Value()
Div & Yield %
25.92
10
0.16
 

sharanam infraproject & trading ltd
Lupin receives USFDA approval for Modafinil Tablets USP
Sep 04,2026
Lupin has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Modafinil Tablets USP, 100 mg and 200 mg.

The U.S. FDA has approved Lupin's Modafinil Tablets USP, 100 mg and 200 mg as bioequivalent to the reference listed drug (RLD), Provigil® Tablets of Nuvo Pharmaceuticals (Ireland) DAC, and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA) or shift work disorder (SWD).

Modafinil Tablets (RLD Provigil®) had estimated annual sales of USD 70.7 million in the U.S. (IQVIA MAT Jul 2026).